Zacks Small Cap Research – LTRN: 2024 Financial Results – Go Health Pro
By John Vandermosten, CFA NASDAQ:LTRN READ THE FULL LTRN RESEARCH REPORT Lantern Pharma, Inc (NASDAQ:LTRN) reports 2024 results highlighting several achievements including progress on its HARMONIC, LP-184 and LP-284 trials, a portfolio of expedited designations in multiple indications and advances in the RADR platform with modules that offer predictive algorithms for blood brain barrier (BBB) … Read more
